B+
Bull case
25%
Probability
Target price
$56.00
Analysis reference price unavailable
Analysis 2026-10-02 · RankAlpha Sentiment Codex
BSX
Boston ScientificCNYSE / Health Care Equipment & Services
Last Price
Quote time unavailable
Current thesis
Q2 sales rose 7.5% and adjusted EPS of $0.86 exceeded the company's $0.82–$0.84 guidance. Cardiovascular sales grew 8.3% reported, and clinical progress supports a longer-term innovation case.
Posture
Mixed
Lead driver
Value
What changed
Next scheduled catalyst: earnings 2026-10-28 · BMO.
What can break
Competitive pressure in U.S. pulsed-field ablation and left-atrial-appendage closure is part of Citi's downgrade thesis. The Fly
Momentum
17
Value
63
Sentiment
45
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $45.00 · Bull $56.00 · Bear $32.00Analysis 2026-10-02; returns require an exact persisted reference.
Earnings
10 · Non-qualifying
Next 2026-10-28 · BMO
Data freshness
Prices
Unavailable: Price unavailable
Fundamentals
As of 2026-10-23 • Vendor: Data Vendor v1
Scores
As of 2026-10-23 • Model: HYBRID_IC_RP
AI Memo
As of 2026-10-02 • Model: RankAlpha Sentiment Codex
Earnings Setup
As of 2026-10-26 • RankAlpha AI
Investment thesisAs of 2026-10-23
Investment thesis
As of 2026-10-23
Grade is the composite factor band; factor scores use a 0–100 scale. Confidence describes evidence quality, not a probability of return. Score date: 2026-10-23. Definitions
Supporting evidence
What
Grade C · Mixed
Confidence Medium · Net Neutral
Target $58.11
Why
Momentum17 · Δ7d +5.2
Value63 · Δ7d +0.1
Sentiment45 · Δ7d -2.9
So what
Balanced signals (Net Neutral). Wait for confirmation before sizing up.
Earnings surprise screen
10Non-qualifying2026-10-28 bmo
Boston Scientific’s official update said manufacturing, fulfillment, and shipping had been restored, but the cyber incident was likely to materially affect Q3 and full-year results; downward estimate revisions and weak recent close-location evidence make an upside-surprise setup unsupported.
Screen as of 2026-10-26. Window 2026-10-26 to 2026-10-30.
Confirming evidence
- • Next scheduled catalyst: earnings 2026-10-28 · BMO.
- • Pre-earnings setup: 10 / non-qualifying.
- • Value remains the lead driver in the composite, 7D delta +0.1.
Contradictions & invalidation
- • Competitive pressure in U.S. pulsed-field ablation and left-atrial-appendage closure is part of Citi's downgrade thesis. The Fly
- • Cyber-related revenue loss, backlog conversion and remediation costs remain unquantified; the company expects a material Q3 and full-year operating impact. [#SEC-8K-2026-09-08]
- • The company reduced its full-year organic-growth outlook from 6.5%–8.0% in April to 5%–6% in July, then warned in September that the cyber incident likely prevents it from meeting the July sales and adjusted-EPS ranges.
Catalyst clock
2026-10-28 · BMO
October 28 outlook reset after cyber disruption
Lead driver: Value · See fundamentals
Momentum
17
8% active weight
Current posture
7d trendImproving
Δ7d
+5.2
Δ21d
+9.7
Value
63
47% active weight
Current posture
7d trendFlat
Δ7d
+0.1
Δ21d
-0.5
Sentiment
45
45% active weight
Current posture
7d trendSoftening
Δ7d
-2.9
Δ21d
-15.0
Why this grade
Composite grade C. Momentum 16.6 / Value 62.8 / Sentiment 45.4
Scenario snapshot
Scenario probability is memo-authored likelihood, not forecast certainty. Targets belong to the analysis dated 2026-10-02. Scenario method
Most likely
B
Base case
45%
Probability
Target price
$45.00
Analysis reference price unavailable
Analysis 2026-10-02 · RankAlpha Sentiment Codex
B-
Bear case
30%
Probability
Target price
$32.00
Analysis reference price unavailable
Analysis 2026-10-02 · RankAlpha Sentiment Codex
Fundamentals (TTM)As of 2026-10-23
Fundamentals (TTM)
As of 2026-10-23
Market Cap
$66.22B
Beta
0.67
Shares Out
1.45B
P/E (TTM)
51.1
P/S (TTM)
7.31
P/FCF (TTM)
37.02
Rev YoY
+7.5%
EPS YoY
+15.3%
Gross Margin
+66.4%
Op Margin
+21.8%
Net Debt
$9.93B
Current Ratio
1.24
As of 2026-10-23 • Updated nightlySource: Internal modelMethods & Data